Clinical Trial

The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The objectives of the proposed study are to investigate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and prliminary efficacy of XH-S004 in moderate to severe COPD patients with a stale standards of care (SOC).
Trial Details
NCT Number NCT07035652
Lead Sponsor S-INFINITY Pharmaceuticals Co., Ltd
Conditions Chronic Obstructive Pulmonary Disease (COPD)
Enrollment 81 participants
Start Date 2025-07-15
Primary Completion 2026-11-13 (estimated)
Study Completion 2026-11-13 (estimated)
Updated on ClinicalTrials.gov 2025-06-25